Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
Market cap is the total market value to buy the whole company. It is equal to the share price times the number of Shares Outstanding (EOP). Suven Life Sciences's share price for the quarter that ended in Mar. 2026 was ₹132.85. Suven Life Sciences's Shares Outstanding (EOP) for the quarter that ended in Mar. 2026 was 263.72 Mil. Therefore, Suven Life Sciences's market cap for the quarter that ended in Mar. 2026 was ₹35,035.33 Mil.
Suven Life Sciences's quarterly market cap
declined
from Sep. 2025 (₹46,256.84 Mil) to Dec. 2025 (₹44,001.85 Mil) and
declined
from Dec. 2025 (₹44,001.85 Mil) to Mar. 2026 (₹35,035.33 Mil).
Suven Life Sciences's annual market cap
increased
from Mar. 2024 (₹21,741.98 Mil) to Mar. 2025 (₹24,729.59 Mil) and
increased
from Mar. 2025 (₹24,729.59 Mil) to Mar. 2026 (₹35,035.33 Mil).
Enterprise Value is the theoretical takeover price. It is more comprehensive than market capitalization (market cap), which only includes common equity. Enterprise Value is calculated as the market cap plus debt and minority interest and preferred shares, minus total cash and cash equivalents. Suven Life Sciences's Enterprise Value for Today is ₹84,826.59 Mil.
Suven Life Sciences (BOM:530239) Market Cap Explanation
Market cap is not the real price you pay for a company. If you buy the company and become its owner, you become the owner of the cash the company has, and you also assume the companys debt. The real price you pay is the Enterprise Value.
Warren Buffett uses the ratio of total market cap of all public traded companies over GDP to measure if the market is expensive. As of April 2012, the US total market cap is about $14.7 trillion, while the US GDP is about $15 trillion. The market was modestly overvalued.
Suven Life Sciences Market Cap Related Terms
Suven Life Sciences Market Cap Historical Data
* Premium members only.
The historical data trend for Suven Life Sciences's Market Cap can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
For the Drug Manufacturers - Specialty & Generic subindustry, Suven Life Sciences's Market Cap, along with its competitors' market caps and Market Cap data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Suven Life Sciences Market Cap vs Drug Manufacturers Industry
For the Drug Manufacturers industry and Healthcare sector, Suven Life Sciences's Market Cap distribution charts can be found below:
* The bar in red indicates where Suven Life Sciences's Market Cap falls into.
Market cap is the short version of market capitalization. It is the total market value to buy the whole company. It is equal to the share price times the number of shares outstanding.
Suven Life Sciences's Market Cap for the fiscal year that ended in Mar. 2026 is calculated as
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Suven Life Sciences (BOM:530239) has a Market Cap of ₹86,548.95 Mil as of Aug. 02, 2026. Market cap equals the total value of a company's shares: price times shares outstanding. View historical data on Suven Life Sciences and its competitors. According to the industry distribution chart, Suven Life Sciences ranks #281 out of 1024 companies in the Drug Manufacturers industry, placing it in the top 27.4%.
Is Suven Life Sciences' Market Cap too high?
Suven Life Sciences' current Market Cap is ₹86,548.95 Mil. Based on the distribution chart, Suven Life Sciences ranks #281 out of 1024 companies in the Drug Manufacturers industry, which is above the industry midpoint. Overall, Suven Life Sciences has a GF Score™ of 41/100 and is considered Significantly Overvalued, reflecting its overall financial health beyond just this single metric.
How does Suven Life Sciences' Market Cap compare to ZTS?
According to the Drug Manufacturers industry distribution chart, Suven Life Sciences ranks #281 out of 1024 companies for Market Cap. This puts Suven Life Sciences in the upper half of its industry. The industry median Market Cap is 210.64. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Market Cap for a Drug Manufacturers company?
The median Market Cap among Drug Manufacturers companies is 210.64, based on 1,024 companies in the industry. Companies in the top quartile (top 25%) have a Market Cap significantly above this median, while those in the bottom quartile fall well below. However, Market Cap should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Market Cap mean?
A high Market Cap can signal that a stock is expensive relative to its fundamentals. Market cap equals the total value of a company's shares: price times shares outstanding. View historical data on Suven Life Sciences and its competitors. For the Drug Manufacturers industry, the median Market Cap is 210.64 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Suven Life Sciences's current Market Cap is ₹86,548.95 Mil. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Suven Life Sciences stock overvalued right now?
Based on GuruFocus' analysis, Suven Life Sciences (BOM:530239) is currently considered Significantly Overvalued. The stock's GF Value™ is ₹97.20, compared to a current price of ₹306.30 — trading 215.1% above its estimated fair value. The current Market Cap is ₹86,548.95 Mil. Suven Life Sciences' overall GF Score™ is 41/100 with 6 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Market Cap calculated?
Market Cap is calculated from a company's financial statements. For Suven Life Sciences (BOM:530239), the current Market Cap is ₹86,548.95 Mil as of Aug. 02, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Suven Life Sciences (BOM:530239) Overvalued in 2026?
Based on GuruFocus' analysis, Suven Life Sciences stock appears to be overvalued.
The current stock price of ₹306.30 is trading 215.1% above its estimated GF Value™ of ₹97.20.
GuruFocus considers Suven Life Sciences to be Significantly Overvalued.
Key valuation signals for BOM:530239:
Market Cap: ₹86,548.95 Mil
GF Value™: ₹97.20 vs. price of ₹306.30 (215.1% above fair value)
No single metric tells the full story. See the BOM:530239 stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Suven Life Sciences Ltd is an India-based biopharmaceutical company. The company is focused on the acquisition, development, and commercialization of novel therapeutics for the treatment of neurodegenerative disorders. The company's only segment is providing Research and Development services. The company's geographical segment includes India; the USA; Europe and Others. The company generates maximum revenue from the USA. The company earns revenue from the sale of New Chemical Entity (NCE) based Intermediates for CNS disorders.
41GF Score
Get the complete analysis for BOM:530239
Market Cap is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
BOM:530239 has been successfully added to your 
